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Background: There has been a significant increase in atypical prescribing for 
children and youths with disruptive behaviour disorder across a range of 
developed countries. (Dean, 2006; Doey, 2007; Harrison Woolrych, 2007; 
Rani 2008; Olfson, 2010).  Controversial new diagnoses, such as disruptive 
mood regulation disorder (Baweja, 2016), and a rise in the use of atypical 
antipsychotic medication in vulnerable child populations, has made the 
diagnostic and prescribing picture for childhood behavioural disorders more 
complex (Greenhill, 2003).   
 
It is important for nurses who are placed in community adolescent mental 
health teams (CAMHS) to be aware of prescribing issues related to the use of 
atypical antipsychotic medication for the children in their care.  The majority of 
atypical antipsychotic prescribing is not conducted by consultant adolescent 
and child psychiatrists (Karanges, 2014), so it is crucial for front-line nursing 
practitioners to be able to offer objective, evidenced-based, balanced advice 
to allied practitioners, families and carers, when considering their use.  Nurses 
are most likely to be the first point of contact for gatekeeping, as well as 
reviewing and monitoring child and adolescent behaviour post prescribing, 
including ongoing risk assessment and management (e.g. NHS England 
2014).  
 
Specified drug use must be seen within the overall context of a holistic blend 
of therapeutic interventions, which involve the use of 1:1 therapeutic 
approaches, multi-systemic family therapy, education and behavioural-
guidance setting. The use of antipsychotic medication should not be used for 
the routine management of problem behaviours in children with conduct 
disorder, or oppositional defiant disorder (NICE, 2013,1.6.1).  Effective 
nursing practice, particularly for CAMHS practitioners, should reflect a 
balanced approach based upon the needs and voice of the child, family and 
associated carers. 
 
  
Objective/s:  
 
To evaluate the effects and safety of atypical antipsychotic medication for 
children and adolescents with a range of disruptive behaviour disorders, as 
compared to a placebo. 
 
To evaluate the effect of each brand of atypical antipsychotic, as opposed to 
the whole class effect. 
 
Intervention/Methods:  The review included randomised-controlled, double-
blinded trials of children and adolescents up to and including 18 years of age 
with a diagnosed disruptive behaviour disorder, who were prescribed atypical 
antipsychotic medication, with those not prescribed medication as a control 
group.  The studies covered children in any setting and included participants 
who had a comorbid diagnosis of ADHD, major depression, anxiety disorders 
or intellectual disability.  Children with a comorbid diagnosis of pervasive 
developmental disorders, psychotic disorder, mood disorder, or autistic 
spectrum disorder were excluded from the study.  The intention was to 
exclude studies where antipsychotic medication was being used to treat 
symptoms other than conduct disorder. 
 
The review included studies of any atypical antipsychotic delivered by any 
means of delivery, for any duration, compared to placebo.  Trials that involved 
the use of other medication, including additional associated psychosocial 
interventions were also eligible for inclusion to reflect ‘real life’ situations as 
mirrored in everyday clinical practice.   
 
Intended outcome measures were reductions in the levels of aggressive 
behaviour, reductions in relation to conduct or disruptive behaviour problems, 
and any adverse events, such as weight gain or related to metabolic 
parameters.  Intended time points for analysis of outcome measures were six 
weeks and six months.   
 
  
Results:  10 studies, conducted between 2000 and 2014, were included in 
the review. Most (n = 8) included outpatients and in eight studies there were 
significantly more males than females. Of the 10 included studies, eight 
investigated the effect of risperidone, one quetiapine and the other 
ziprasidone.  Consequently, it was only possible to evaluate the effects of 
risperidone by meta-analysis. 
 
Results of a meta-analysis of three studies (238 children) suggested that 
risperidone reduced aggression at the six-week period, but the evidence for 
this was of low quality.  Results of a meta-analysis of two studies (225 
children) found that risperidone also led to reductions in conduct problems 
after six weeks of treatment, and the evidence for this was of moderate 
quality. 
 
Levels of weight gain were significantly higher in children given either 
risperidone (2.37 kg higher; two studies, 138 children) or risperidone and a 
stimulant (2.14 kg higher; three studies, 305 children), than those given 
placebo, over the six to 10-week treatment period. 
 
Conclusions:  The review found some evidence that risperidone reduces 
aggression and conduct problems in children and youths with disruptive 
behaviour disorders. Both findings could be clinically significant, but should be 
interpreted with caution due to the small number of high-quality trials.   
 
There is some concern with regards to weight gain associated with the use of 
risperidone over the treatment period.  It is unclear whether this would 
attenuate or become a significant clinical issue over time. 
 
The limited strength of the evidence suggests that the use of risperidone 
should be carefully considered. Medication should be used with, or preceded 
by effective psychosocial treatments. This is consistent with current clinical 
guidance, which states that medication should not be used alone as a method 
to reduce levels of aggression and conduct problems in a largely vulnerable 
and complex population. 
  
 
Implications for Practice: There is limited but useful evidence to suggest 
that risperidone could be effective in reducing levels of aggression and 
conduct problems in children with disruptive behaviour disorders in the short 
term.  This should be offset with considerations relating to likely weight gain 
and the consequent clinical and sociological impacts to a child. 
 
The role of the nurse in monitoring prescribing is key to the area of CAMHS 
provision.  The majority of children with disruptive behaviour disorder are 
likely to be managed within non-clinical environments such as the home and 
single agencies such as schools, general practitioner surgeries, social 
services, criminal justice agencies and education welfare services.  The 
primary role for the CAMHS nurse will involve a signposting and gatekeeping 
role when individuals and agencies seek advice on how to manage disruptive 
behaviour.  It is possible that the question of whether to prescribe atypical 
psychotic medication may arise in these discussions.  The use of these 
medications need to be contextualised within the current framework of 
treatment and care, which includes a range of effective bio-psychosocial 
interventions, as prescribed via NICE guidance. 
 
For those children who meet the threshold of CAMHS provision, the role of 
the nurse will be integral with regards risk management, intervention and 
ongoing therapeutic treatment of the child.  The presence of some form of 
disruptive behaviour disorder is likely to be a primary cause for referral.  The 
use of atypical antipsychotic medication is one intervention which given the 
limited strength of evidence, should be considered with caution and never as 
an isolated intervention. 
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